Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bolis

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Journal of Hematotherapy|October 1, 1995
Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directionsS Canevari, D Mezzanzanica, A Mazzoni, et al.
Cancer|January 1, 1996
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomyG Bolis, A Villa, P Guarnerio, et al.
Journal of Medicinal Chemistry|October 28, 1997
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor bindingF Heidempergher, A Pillan, V Pinciroli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1997
Experience with independent radiological review during a topotecan trial in ovarian cancerS Gwyther, G Bolis, M Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Potentials of cell kinetics in the management of patients with ovarian cancersR Silvestrini, M G Daidone, B Valentinis, et al.
Journal of the National Cancer Institute|October 4, 1989
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatinC Mangioni, G Bolis, S Pecorelli, et al.
Gynecologic Oncology|March 30, 2001
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancerG Bolis, G Scarfone, G Giardina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1995
Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia OncologicaG Bolis, N Colombo, S Pecorelli, et al.
Cancer|January 15, 1998
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocolR Silvestrini, M G Daidone, S Veneroni, et al.
British Journal of Cancer|September 1, 1990
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG))S Marsoni, V Torri, M G Valsecchi, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Journal of Hematotherapy|October 1, 1995
Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directionsS Canevari, D Mezzanzanica, A Mazzoni, et al.
Cancer|January 1, 1996
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomyG Bolis, A Villa, P Guarnerio, et al.
Journal of Medicinal Chemistry|October 28, 1997
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor bindingF Heidempergher, A Pillan, V Pinciroli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1997
Experience with independent radiological review during a topotecan trial in ovarian cancerS Gwyther, G Bolis, M Gore, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Potentials of cell kinetics in the management of patients with ovarian cancersR Silvestrini, M G Daidone, B Valentinis, et al.
Journal of the National Cancer Institute|October 4, 1989
Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatinC Mangioni, G Bolis, S Pecorelli, et al.
Gynecologic Oncology|March 30, 2001
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancerG Bolis, G Scarfone, G Giardina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1995
Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia OncologicaG Bolis, N Colombo, S Pecorelli, et al.
Cancer|January 15, 1998
The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocolR Silvestrini, M G Daidone, S Veneroni, et al.
British Journal of Cancer|September 1, 1990
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG))S Marsoni, V Torri, M G Valsecchi, et al.
Pageof 13